These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38276986)

  • 21. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
    Hernandez R; Czerwinski A; Chakravarty R; Graves SA; Yang Y; England CG; Nickles RJ; Valenzuela F; Cai W
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical translation of a novel FAPI dimer [
    Tan Y; Li J; Zhao T; Zhou M; Liu K; Xiang S; Tang Y; Jakobsson V; Xu P; Chen X; Zhang J
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2761-2773. PubMed ID: 38561515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation.
    Knetsch PA; Zhai C; Rangger C; Blatzer M; Haas H; Kaeopookum P; Haubner R; Decristoforo C
    Nucl Med Biol; 2015 Feb; 42(2):115-22. PubMed ID: 25459110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
    Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of α
    Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
    J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
    Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
    J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging integrin αvβ 3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe.
    Wu H; Chen H; Pan D; Ma Y; Liang S; Wan Y; Fang Y
    Mol Imaging Biol; 2014 Dec; 16(6):781-92. PubMed ID: 25001194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin α
    Yang B; Shan C; Song X; Lv X; Long Y; Zeng D; An R; Lan X; Gai Y
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3334-3345. PubMed ID: 38787395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the
    Läppchen T; Bilinska A; Pilatis E; Menéndez E; Imlimthan S; Moon ES; Afshar-Oromieh A; Rösch F; Rominger A; Gourni E
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38999044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Evaluation of
    Galbiati A; Bocci M; Ravazza D; Mock J; Gilardoni E; Neri D; Cazzamalli S
    J Nucl Med; 2024 Oct; 65(10):1604-1610. PubMed ID: 39266289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
    Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
    Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evaluation of a dual-receptor targeted tracer [
    Lv X; Song X; Long Y; Zeng D; Lan X; Gai Y
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):54-67. PubMed ID: 37642706
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Zhang J; Mao F; Niu G; Peng L; Lang L; Li F; Ying H; Wu H; Pan B; Zhu Z; Chen X
    Theranostics; 2018; 8(4):1121-1130. PubMed ID: 29464003
    [No Abstract]   [Full Text] [Related]  

  • 39. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.
    Dijkgraaf I; Yim CB; Franssen GM; Schuit RC; Luurtsema G; Liu S; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):128-37. PubMed ID: 20857099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.